The statin wars: why AstraZeneca must retreat.
D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004345:Drug Industry / Q000191:economics / Q000941:ethics*; D005464:Fluorobenzenes / Q000191:economics / Q000592:standards* / Q000600:supply & distribution; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000600:supply & distribution*; D008389:Marketing of Health Services / Q000941:ethics* / Q000379:methods / Q000592:standards; D011743:Pyrimidines / Q000191:economics / Q000592:standards* / Q000600:supply & distribution; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000191:economics / Q000592:standards* / Q000600:supply & distribution; D016896:Treatment Outcome
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium